Cancer Biopsy Market Size to Hit US$ 40.65 Bn by 2030

According to Vision Research Reports, the global Cancer Biopsy market size is estimated to hit around US$ 40.65 billion by 2030 from valued at US$ 21.8 billion in 2020, growing at a CAGR of 10.35% from 2021 to 2030.

Growth Factors

Several methods of diagnosing cancer patients exist currently, however, biopsy remains to be the only definitive method to confirm the onset of the disease in a patient. Since it involves close examination of organs/tissues, doctors largely rely on biopsies to perform accurate and early diagnosis in susceptible patients.

There has been a significant transition from tumor to which is expected to increase the adoption of kits as well as consumables. Acknowledging this trend, various market players have invested in the development of novel kits in order to expand their biopsy kits portfolio. For instance, Biocept, Inc. recently launched a liquid biopsy kit that is designed for research use pertaining to gene mutations.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/36658

Scope of the Report

Additionally, tumor biopsy is most adopted for the diagnosis on individual levels, along with monitoring the effects of ongoing oncology treatment. Shortcomings of liquid biopsies such as lack of robust efficacy evaluations and their associated high costs are currently bridged by tissue biopsies. This has made tissue biopsy a gold-standard procedure in the present diagnostic scenario.

Moreover, revolutionary advancements in liquid biopsies are expected to be a key factor fueling the overall market growth. Liquid biopsies are expected to offer lucrative opportunities in the field of genomic data analysis and oncology-based personalized medicine. Key players operating in the market such as Cardinal Health; BD; and Biocept, Inc. are focusing on the development of novel or automated biopsies to sustain the current market competition.

Report Highlights

Kits and consumables led the market and accounted for over 60.02% share in 2020 as these are integral across various stages of biopsies and robust investments by key players operating in this industry have made significant contributions. This is also supplemented by a considerable increase in the number of patients across the globe that demand instruments and kits to be efficient, accurate, and rapid.

Cancer biopsy has witnessed several developments in terms of instruments, kits, and consumables. With liquid biopsy emerging as a multimodal tool of diagnosis in the field of clinical oncology, the development of efficient products associated with biopsies is pivotal. Though the existing instruments are used predominantly, they are accompanied by various shortcomings. However, the advent of novel technologies is expected to significantly increase the demand for instruments in the coming years.

Several emerging manufacturers are focusing on launching instruments that are able to enhance endoscopy-based biopsies. For instance, BiBBInstruments AB, a Swedish company, has established a strong presence in the instruments market space under the brand - EndoDrill.

The tissue biopsies segment dominated the market and accounted for 86.05% share of the total revenue in 2020. These are still considered to be a mainstay of biopsies and are largely adopted across various cancer diagnosis applications. This is attributed to robust research activities evaluating their safety and efficacy, which has contributed to the segment growth in the global market.

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36658

Advancements targeted towards enhancing tissue biopsy procedures are expected to maintain the segment’s lead in the global market for the next few years. For instance, Cernostics is developing an assay suitable for diagnosing cancer patients suffering from Barrett's Esophagus. This one-of-a-kind diagnostic test makes use of biopsy images that are digitally scanned, which aids in the analysis and quantification of alterations occurring at the cellular or molecular levels within a tissue.

Technological developments pertaining to circulating biomarkers detection in blood samples derived from patients allow non-hematologic cancer diagnosis through non-invasive techniques. is considered to be a more practical approach to real-time patient monitoring as compared to conventional tumor biopsies.

Liquid biopsy tests are inclusive of markers such as circulating tumor DNA (ctDNA), (CTCs), and extracellular vesicles (EVs). Exosomes are known to have the ability to alter treatment and manage the dynamics related to disease progression.

The rising preference for liquid biopsy among physicians has been observed in recent years, which is supplemented by its ability to offer disease snapshots from the primary and distant tumor sites. This approach is put to use in personalized medicine treatment, wherein tumor markers are sampled repeatedly to alter the therapy based on the patient’s response to the treatment.

Breast cancer emerged as the dominant segment and accounted for over 14.02% share of the total revenue in 2020. Breast cancer has the largest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. An estimated 276,480 new cases of invasive breast cancer are expected to be diagnosed in women in 2020 in the U.S., along with more than 40,000 new non-invasive breast cancer cases.

Patients suspected of the onset of breast cancer are subjected to microscopic analysis of breast tissue, which is mandatory to obtain a definitive diagnosis along with detecting the stage and characterization of type. This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis, in turn, contributing to the segment growth.

North America held the largest revenue share of over 37.02% in 2020. North America is anticipated to maintain its lead throughout the forecast, with the U.S. making significant contributions to the regional revenue. In addition, distributors and manufacturers operating in this region aim to distribute as well as develop novel kits that are well-suited for rapid diagnostic applications.

Moreover, the increasing adoption of liquid biopsies across the U.S. is largely favored by the profitable strategies laid out by the respective government authorities. Regulatory strategies for liquid biopsy-based oncology diagnostics rely on the framework, which has been developed in recent years by the U.S. Food and Drug Administration (FDA).

Key Players

• Qiagen N.V.
• Illumina, Inc.
• ANGLE Plc
• BD (Becton, Dickinson And Company)
• Myriad Genetics
• Hologic, Inc.
• Biocept, Inc.
• Thermo Fisher Scientific, Inc.
• Danaher
• F. Hoffmann-La Roche Ltd.
• Lucence Diagnostics Pte. Ltd.
• GRAIL, Inc.
• Guardant Health
• Exact Sciences Corporation
• Freenome Holdings, Inc.
• Biodesix (Integrated Diagnostics)
• Oncimmune
• Epigenomics AG
• HelioHealth (Laboratory for Advanced Medicine)
• Genesystems, Inc. (GenesysBiolabs)
• Chronix Biomedical, Inc.
• Personal Genome Diagnostics Inc.
• Natera, Inc.
• Personalis Inc.

Market Segmentation

• Product Outlook
  • Instruments
  • Kits and Consumables
  • Services
• Type Outlook
  • Tissue Biopsies
    • Needle Biopsies
      • Fine Needle Aspiration (FNA)
      • Core Needle Biopsy (CNB)
    • Surgical Biopsies
  • Liquid Biopsies
  • Others
• Application Outlook
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancers
  • Lung Cancers
  • Prostate Cancers
  • Skin Cancers
  • Blood Cancers
  • Kidney Cancers
  • Liver Cancers
  • Pancreatic Cancers
  • Ovarian Cancers
  • Others
• Regional Outlook 
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36658

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333